Cas:85612-59-5 (2R)-3-phenylpropane-1,2-diamine manufacturer & supplier

We serve Chemical Name:(2R)-3-phenylpropane-1,2-diamine CAS:85612-59-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(2R)-3-phenylpropane-1,2-diamine

Chemical Name:(2R)-3-phenylpropane-1,2-diamine
CAS.NO:85612-59-5
Synonyms:(2R)-3-phenylpropane-1,2-diamine
Molecular Formula:C9H14N2
Molecular Weight:150.22100
HS Code:2921590090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:284.8ºC at 760 mmHg
Density:1.025g/cm3
Index of Refraction:1.561
PSA:52.04000
Exact Mass:150.11600
LogP:1.91570

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (2R)-3-phenylpropane-1,2-diamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2R)-3-phenylpropane-1,2-diamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2R)-3-phenylpropane-1,2-diamine Use and application,(2R)-3-phenylpropane-1,2-diamine technical grade,usp/ep/jp grade.


Related News: Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. (2R)-3-phenylpropane-1,2-diamine manufacturer In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better. (2R)-3-phenylpropane-1,2-diamine supplier Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition. (2R)-3-phenylpropane-1,2-diamine vendor We partner with life science companies of all sizes, drawing on over 20 years of industry experience. (2R)-3-phenylpropane-1,2-diamine factory Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.